As of November 7, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Nano Dimension Ltd. The largest reported stake is Murchinson Ltd.'s, at 10.1%. 13 filings are on record since July 3, 2025 (Schedule 13D/A, October 29, 2026).
Sell to companies like Nano Dimension Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Murchinson Ltd. · Sole voting: 10,208,249 · Shared voting: 10,208,251 · Sole dispositive: 10,208,249 · Shared dispositive: 10,208,251 · SCHEDULE 13D/A, 2026-10-29
- · Reporting person: Tang Capital Management, LLC · Sole voting: 0 · Shared voting: 19,232,538 · Sole dispositive: 0 · Shared dispositive: 19,232,538 · SCHEDULE 13G, 2026-08-21
- · Holder: Tang Capital Management, LLC · Percent: 7.9% · SCHEDULE 13D/A
- · Reporting person: Oramed Pharmaceuticals Inc. · Sole voting: 6,879,708 · Shared voting: 0 · Sole dispositive: 6,879,708 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-07-22
- · Holder: Murchinson Ltd. · Percent: 8.1% · SCHEDULE 13D/A
Nano Dimension Ltd. has 13 Schedule 13D or 13G filings on record since 2025-07-03. 2 holders' latest filing reports 5% or more of ordinary shares par value nis 5.00 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Murchinson Ltd. | 10.1% | 20,416,500 | SCHEDULE 13D/A, 2026-10-29 | 2026-10-22 |
| Tang Capital Management, LLC | 9.1% | 19,232,538 | SCHEDULE 13G, 2026-08-21 | 2026-08-19 |
| Anson Funds Management LP | 4.2% | 9,057,952 | SCHEDULE 13D/A, 2025-07-14 | 2025-07-11 |
| Oramed Pharmaceuticals Inc. | 3.3% | 6,879,708 | SCHEDULE 13D/A, 2026-07-22 | 2026-07-20 |
Holding shares or following this stake? See who's behind Nano Dimension Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on Nano Dimension Ltd. and the records around it.
Nano Dimension Ltd. elsewhere on the record
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- Murchinson Ltd. also filed stake reports on 2 other companies: Valion Bio, Inc. (Jul 2026), Pelthos Therapeutics Inc. (Nov 2025)
- Oramed Pharmaceuticals Inc. also filed stake reports on 2 other companies: Lifeward Ltd. (May 2026), Scilex Holding Co (Feb 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Capricor Therapeutics, Inc. (Aug 2026)
Watch Nano Dimension Ltd.
Get an email when Nano Dimension Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Nano Dimension Ltd.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Nano Dimension Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nano Dimension Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Murchinson Ltd. | 10,208,249 | 10,208,251 | 10,208,249 | 10,208,251 | SCHEDULE 13D/A, 2026-10-29 |
| Nomis Bay Ltd. | 0 | 6,135,800 | 0 | 6,135,800 | SCHEDULE 13D/A, 2026-10-29 |
| BPY Ltd. | 0 | 4,072,451 | 0 | 4,072,451 | SCHEDULE 13D/A, 2026-10-29 |
| EOM Management Ltd. | 0 | 10,208,251 | 0 | 10,208,251 | SCHEDULE 13D/A, 2026-10-29 |
| James Keyes | 0 | 10,208,251 | 0 | 10,208,251 | SCHEDULE 13D/A, 2026-10-29 |
| Jason Jagessar | 0 | 10,208,251 | 0 | 10,208,251 | SCHEDULE 13D/A, 2026-10-29 |
| Chaja Carlebach | 0 | 10,208,251 | 0 | 10,208,251 | SCHEDULE 13D/A, 2026-10-29 |
| Clarendon Hugh Masters | 0 | 10,208,251 | 0 | 10,208,251 | SCHEDULE 13D/A, 2026-10-29 |
| Marc J. Bistricer | 10,208,249 | 10,208,251 | 10,208,249 | 10,208,251 | SCHEDULE 13D/A, 2026-10-29 |
| Tang Capital Management, LLC | 0 | 19,232,538 | 0 | 19,232,538 | SCHEDULE 13G, 2026-08-21 |
| Kevin Tang | 0 | 19,232,538 | 0 | 19,232,538 | SCHEDULE 13G, 2026-08-21 |
| Tang Capital Partners, LP | 0 | 4,407,468 | 0 | 4,407,468 | SCHEDULE 13G, 2026-08-21 |
| Tang Capital Partners International, LP | 0 | 6,010,162 | 0 | 6,010,162 | SCHEDULE 13G, 2026-08-21 |
| Tang Capital Partners Iii, Inc | 0 | 4,407,456 | 0 | 4,407,456 | SCHEDULE 13G, 2026-08-21 |
| Tang Capital Partners Iv, Inc | 0 | 4,407,452 | 0 | 4,407,452 | SCHEDULE 13G, 2026-08-21 |
| Oramed Pharmaceuticals Inc. | 6,879,708 | 0 | 6,879,708 | 0 | SCHEDULE 13D/A, 2026-07-22 |
The latest filing identifies Nano Dimension Ltd. by CUSIP 63008G203 and gives its principal executive office as 60 TOWER ROAD, WALTHAM, MA 02451 (SCHEDULE 13D/A, 2026-10-29).
Source of funds (Item 3)
Item 3 is hereby amended and restated to read as follows: The Shares purchased by Nomis Bay were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 6,135,800 Shares beneficially owned by Nomis Bay is approximately $16,250,051, including brokerage commissions. In addition, in connection with the prior ADS conversions, Nomis Bay paid $270,000 in fees to the Bank of New York Mellon, as depositary.Murchinson Ltd., SCHEDULE 13D/A, 2026-10-29
Item 3 is hereby amended and supplemented as follows: "In open market purchases on July 20, 2026, the Reporting Person expended an aggregate of approximately $1,258,000 (excluding commissions) to purchase call options referencing an aggregate of 8,200,000 Ordinary Shares. The funds used for the purchase of the securities reported in this Schedule 13D were derived from the general working capital of the Reporting Person."Oramed Pharmaceuticals Inc., SCHEDULE 13D/A, 2026-07-22
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-03 | Anson Funds Management LP | 7.5% | SCHEDULE 13D/A |
| 2025-07-14 | Anson Funds Management LP | 4.2% | SCHEDULE 13D/A |
| 2026-01-29 | Oramed Pharmaceuticals Inc. | 5% | SCHEDULE 13D |
| 2026-02-19 | Oramed Pharmaceuticals Inc. | 5.2% | SCHEDULE 13D/A |
| 2026-05-21 | Murchinson Ltd. | 7.4% | SCHEDULE 13D/A |
| 2026-06-17 | Oramed Pharmaceuticals Inc. | 7.2% | SCHEDULE 13D/A |
| 2026-06-23 | Murchinson Ltd. | 9.6% | SCHEDULE 13D/A |
| 2026-06-30 | Tang Capital Management, LLC | 6.8% | SCHEDULE 13D |
| 2026-07-20 | Murchinson Ltd. | 8.1% | SCHEDULE 13D/A |
| 2026-07-22 | Oramed Pharmaceuticals Inc. | 3.3% | SCHEDULE 13D/A |
| 2026-07-27 | Tang Capital Management, LLC | 7.9% | SCHEDULE 13D/A |
| 2026-08-21 | Tang Capital Management, LLC | 9.1% | SCHEDULE 13G |
| 2026-10-29 | Murchinson Ltd. | 10.1% | SCHEDULE 13D/A |
Questions about who owns Nano Dimension Ltd.
Who owns Nano Dimension Ltd.?
On this page, 2 holders' latest ownership filings report 5% or more of Nano Dimension Ltd.: Murchinson Ltd. (10.1%, Schedule 13D/A, filed 2026-10-29) and Tang Capital Management, LLC (9.1%, Schedule 13G, filed 2026-08-21).
Who are the largest shareholders of Nano Dimension Ltd.?
By the share each holder's latest filing reports, the largest holders of Nano Dimension Ltd. on this page are Murchinson Ltd. (10.1%) and Tang Capital Management, LLC (9.1%).
When did Murchinson Ltd. buy into Nano Dimension Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Murchinson Ltd. on this page is the Schedule 13D/A, filed 2026-05-21, reporting 7.4%; its latest, Schedule 13D/A filed 2026-10-29, reports 10.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Nano Dimension Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Leadership change: Moshe Rozenbaum appointed, Chief Executive Officer | — | Leadership changes | Source |
| July 21, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Nano Dimension Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.